Oculis announced that its Phase 3 DIAMOND trials for OCS-01 eye drops in diabetic macular edema did not meet the primary endpoint of improved visual acuity after 52 weeks. However, the treatment showed significant and lasting reduction in retinal thickness, a secondary measure. The drug was well tolerated with no unexpected side effects. Oculis will not pursue FDA approval for OCS-01 for this condition but will focus on other drug candidates, including Privosegtor for optic nerve disorders and Licaminlimab for dry eye disease. The company maintains strong financial health with cash to fund operations through late 2029.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ERock, Inc. received a buy rating due to its innovative modular natural-gas power systems that help data centers avoid long waits for permanent grid power. The company has a strong $1.3 billion backlog supported by customer deposits, providing clear ...
IBM's business model remains strong despite a 7% decline in mainframe infrastructure revenue, supported by loyal legacy customers and solid free cash flow. Software growth, especially an 11% increase in Red Hat revenue, helps offset mainframe challen...
BMW is recalling 29,119 plug-in hybrid sedans due to a potential fire risk caused by corrosion in the engine starter's electrical relay. This defect can lead to a short circuit and overheating even when the vehicle is parked with the ignition off. Th...
The Fidelity Fundamental Large Cap Core ETF (FFLC) provides an actively managed alternative to traditional S&P 500 index funds by emphasizing risk-adjusted returns and fundamental company strength. FFLC excludes companies with high valuations and low...
